BWAY
Overvalued by 168.3% based on the discounted cash flow analysis.
Market cap | $170.22 Million |
---|---|
Enterprise Value | $112.50 Million |
Dividend Yield | $0 (0%) |
Earnings per Share | $0.18 |
Beta | 0.16 |
Outstanding Shares | 18,813,213 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 54.57 |
---|---|
PEG | -14.07 |
Price to Sales | 4.44 |
Price to Book Ratio | 2.96 |
Enterprise Value to Revenue | 2.91 |
Enterprise Value to EBIT | 56.99 |
Enterprise Value to Net Income | 74 |
Total Debt to Enterprise | 0.1 |
Debt to Equity | 0.19 |
No data
No data
Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the tr...